Health coverage company Centene (NYSE: CNC) will be reporting earnings this Friday before market open. Here’s what investors should know.

Centene beat analysts’ revenue expectations by 3.7% last quarter, reporting revenues of $49.69 billion, up 18.2% year on year. It was an exceptional quarter for the company, with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates. It lost -36,800 customers and ended up with a total of 27.97 million.

Is Centene a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Centene’s revenue to grow 18.3% year on year to $48.26 billion, improving from the 3.4% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$1.22 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Centene has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 8.4% on average.

Looking at Centene’s peers in the health insurance providers segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Cencora delivered year-on-year revenue growth of 5.5%, missing analysts’ expectations by 0.6%, and UnitedHealth reported revenues up 12.3%, in line with consensus estimates. UnitedHealth traded down 16.4% following the results.

Read our full analysis of Cencora’s results here and UnitedHealth’s results here.

Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the health insurance providers stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4% on average over the last month. Centene is down 10.6% during the same time and is heading into earnings with an average analyst price target of $43.88 (compared to the current share price of $40.87).

P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.